Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemoradiation for Locally Advanced Laryngeal Squamous Cell Carcinoma
NCT02759575Phase 2Completed
- Start
- Apr 2016
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in laryngeal squamous cell carcinoma (LSCC). Started Apr 2016; status: completed.
02
Drugs
03
Conditions
laryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on NCT02759575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759575.